-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

DOACs: role of anti-Xa and Drug Level Monitoring

Program: Education Program
Session: Anticoagulation SOS: Navigating Monitoring Conundrums
Hematology Disease Topics & Pathways:
Education
Monday, December 9, 2024, 10:30 AM-11:45 AM

Deborah Siegal, MD, MSc

Department of Medicine, University of Ottawa, Ottawa, ON, Canada

Disclosures: Siegal: Servier: Other: honoraria paid indirectly to research institute; Roche: Other: honoraria paid indirectly to research institute; BMS-Pfizer: Other: honoraria paid indirectly to research institute; Astra Zeneca: Other: honoraria paid indirectly to research institute.

See more of: Anticoagulation SOS: Navigating Monitoring Conundrums
See more of: Education Program
Previous Presentation | Next Presentation >>